Adjuvant trastuzumab emtansine (Kadcyla; T-DM1)
USA
Technology
+44018956955324
2ntakh934o@illubd.com
Added on 28 Mar 2025
6-9 The Square, Stockley Park, Uxbridge, Middlesex UB11 1FW
Business Description
“This prespecified long-term follow-up analysis provides additional support for the neoadjuvant therapy paradigm by showing that adjuvant T-DM1 also provided a significant improvement in overall survival and no evidence of long-term safety issues,” wrote KATHERINE investigators in The New England Journal of Medicine.
Patients enrolled in the phase 3, open-label trial continued to see an improvement in invasive disease-free survival with T-DM1 vs trastuzumab at a median follow-up of 8.4 years (unstratified HR = 0.54; 95% CI, 0.44-0.66). Particularly, 19.7% of patients in the T-DM1 group and 32.2% of patients in the trastuzumab group experienced invasive disease events or death.
Seven-year invasive disease-free survival was achieved in 80.8% of patients treated with T-DM1 and 67.1% of patients on trastuzumab (difference, 13.7 percentage points).
The trial included patients with HER2-positive early breast cancer who had received neoadjuvant treatment, which included a taxane-based chemotherapy and/or trastuzumab, and had residual invasive cancer in the breast or resected axillary nodes. Patients were randomly assigned to receive either T-DM1 (n = 743) or trastuzumab (n = 743). Patients were stratified by clinical stage, hormone-receptor status, preoperative HER2-directed therapy, and pathological nodal status after neoadjuvant therapy.
T-DM1 significantly reduced the risk for death compared with trastuzumab (unstratified HR = 0.66; 95% CI, 0.51-0.87; P = .003). Seven-year overall survival for the T-DM1 and trastuzumab groups were 89.1% and 84.4%, respectively (difference, 4.7 percentage points). As of the trial’s cutoff date of October 5, 2023, 70.1% of patients assigned T-DM1 and 62.0% of patients assigned trastuzumab were alive and still in the trial.
Deaths occurred in 89 patients (12.0%) in the T-DM1 group and 126 patients (17.0%) in the trastuzumab group. Of these deaths, 70 (79%) and 108 (86%) patients, respectively, died from breast cancer.
Adverse events (AEs) grade 3 or higher occurred in 26.1% of patients treated with T-DM1 and 15.7% of patients treated with trastuzumab. Serious AEs occurred in 12.7% and 8.1% of patients, respectively.
Post-treatment AEs were less common for both groups but still more prevalent in the T-DM1 group, with 3.2% and 1.7% of patients assigned T-DM1 and trastuzumab, respectively, experiencing AEs of any grade during this period.
https://www.twosapp.com/67e5bc42795e95113cfa23a6
https://talkfever.com/posts/36877
https://hallbook.com.br/posts/514191
https://wegug.in/posts/54582
https://forum.phuongnamedu.vn/threads/nanonano-mencretcalan-ciritlele.8344/
https://dangtinvantai.com/threads/nanonano-mencretcalan-ciritlele.63658/
https://chobaolam.vn/threads/nanonano-mencretcalan-ciritlele.633132/
https://choitrai.net/threads/nanonano-mencretcalan-ciritlele.50203/
https://chodilinh.com/threads/nanonano-mencretcalan-ciritlele.456427/
https://diendannhansu.com/threads/nanonano-mencretcalan-ciritlele.754834/
https://ecency.com/cocot/@susutjitangvi/nanonano-mencretcalan-ciritlele
https://forum.thecodingcolosseum.com/topic/49810/nanonano-mencretcalan-ciritlele
https://foro.ribbon.es/topic/66767/nanonano-mencretcalan-ciritlele
https://icimodels.com/advert/nanonano-mencretcalan-ciritlele/
https://haitiliberte.com/advert/nanonano-mencretcalan-ciritlele/
https://feiradevelharias.com/advert/nanonano-mencretcalan-ciritlele/
https://taylorhicks.ning.com/photo/albums/nanonano-mencretcalan-ciritlele
https://healingxchange.ning.com/photo/albums/nanonano-mencretcalan-ciritlele
https://findaspring.org/members/susutjincine/
https://bootstrapbay.com/user/acisampeuedol
https://nexusstem.co.uk/community/main-forum/nanonano-mencretcalan-ciritlele/
https://www.deviantart.com/stevianaomi/journal/nanonano-mencretcalan-ciritlele-1176063173
https://app.daily.dev/posts/nanonano-mencretcalan-ciritlele-1k8ebenju
https://hackmd.io/@stevaniachaw/rJ7WHSmT1g
Frequently Asked Questions
➤ What services does Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) offer?
Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) provides professional Technology services for customers in USA, . They focus on delivering quality solutions tailored to client needs.
➤ Where is Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) located?
This business is located in USA, , making it a convenient choice for local customers looking for reliable Technology services.
➤ How can I contact Adjuvant trastuzumab emtansine (Kadcyla; T-DM1)?
You can contact Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) via phone or email listed on this page to learn more about their services and availability.
➤ Why choose Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) over other Technology providers?
Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) is known for professionalism, customer satisfaction, and dependable service, making it a trusted choice for Technology needs in USA.
Services Offered by Adjuvant trastuzumab emtansine (Kadcyla; T-DM1)
Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) provides a range of Technology services designed to meet customer needs efficiently. Their services are tailored for individuals and businesses seeking reliable and professional support.
- Professional Technology consultation
- Customer-focused service approach
- Affordable and transparent pricing
- Timely project delivery
Business Hours
This business typically operates during standard working hours. Customers are encouraged to contact the business directly to confirm current availability and service timings.
Customer Support
Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) values customer satisfaction and provides dedicated support to address inquiries and service requests. Their team ensures a smooth experience from initial contact to service completion.
Local USA Business Information
Adjuvant trastuzumab emtansine (Kadcyla; T-DM1) proudly serves customers in USA, . As a local business, it understands the needs of the community and provides services that align with regional requirements.
